{
    "clinical_study": {
        "@rank": "142955", 
        "acronym": "SNORE", 
        "brief_summary": {
            "textblock": "This is a prospective, interventional, study in which patients with a history of habitual\n      snoring to determine whether low pressure nasal continuous airway pressure can reduce the\n      frequency, duration or intensity of snoring in subjects with mild to moderate snoring who do\n      not have Obstructive Sleep Apnea (OSA)."
        }, 
        "brief_title": "Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Habitual, Simple Snoring", 
        "condition_browse": {
            "mesh_term": "Snoring"
        }, 
        "detailed_description": {
            "textblock": "In this a prospective, interventional, study, each patient will be studied four times.\n      Subjects without OSA will undergo an initial observational control study to establish the\n      presence of snoring (session 1); a single CPAP titration night to determine the minimally\n      effective CPAP level (session 2) to alleviate snoring; a subsequent full night of CPAP\n      treatment at this CPAP level (CPAP not to exceed 6 cm H2O) using the Cloud9\u2122 low-pressure\n      CPAP device (session 3); and a final control night of study conducted off CPAP to assess\n      whether the patient's snoring remained stable over time (session 4).  In this study, each\n      subject shall serve as his/her own control."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is > 18 years of age.\n\n          -  Subject is willing and able to provide written Informed Consent using a  Patient\n             Information and Consent form that has been reviewed and approved by a governing\n             Institutional Review Board (IRB).\n\n          -  Subject has a history of habitual snoring (almost every night or every night for at\n             least 30% of the night) as determined by the subject or a bed-partner.\n\n          -  Subject has been pre-screened and demonstrates no excess daytime sleepiness on an\n             Epworth Questionnaire (an assessment of daytime sleepiness; high number = greater\n             sleepiness) score of less than 11, no history of witnessed apneas or nocturnal\n             gasping/choking episodes and a body mass index (BMI) \u2264 35.\n\n        Inclusion Criteria for treatment trials (Nights 2 and 3):\n\n          -  Subject meets Inclusion Criteria for the Baseline Trial (criteria a-d above)\n\n          -  The subject has snoring intensity that exceeds 40 dBA during \u226530% of the respiratory\n             efforts during sleep time on the baseline study night.\n\n        Exclusion Criteria:\n\n          -  Subject has been diagnosed with COPD (Chronic Obstructive Pulmonary Disease), such as\n             asthma, emphysema or chronic bronchitis.\n\n          -  Subject has a history of heart disease, heart attack or stroke.\n\n          -  Subject has uncontrolled or poorly controlled hypertension.\n\n          -  Subject has been diagnosed with Obstructive Sleep Apnea (OSA), defined as an apnea\n             hypopnea index (AHI) \u2265 5/hr in the presence of excessive sleepiness (an Epworth score\n             \u2265 11) or AHI \u226515/hr when there is no evidence of excessive daytime sleepiness (an\n             Epworth score \u2264 10).\n\n          -  Subject is currently participating in another clinical study for which follow-up is\n             ongoing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949584", 
            "org_study_id": "IS103-PRO-00002"
        }, 
        "intervention": {
            "description": "Low level continuous positive airway pressure delivered during sleep.", 
            "intervention_name": "nasal continuous positive airway pressure less than or equal to 6 cm H2O", 
            "intervention_type": "Device", 
            "other_name": "Cloud9\u2122 nasal CPAP device and nasal interface"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rharris@neurotrials.com", 
                    "last_name": "Ronna Harris", 
                    "phone": "404-851-9934"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "NeuroTrials Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Russell P. Rosenberg, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mguzman4@jhmi.edu", 
                    "last_name": "Michelle Guzman", 
                    "phone": "410-550-6336"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21224"
                    }, 
                    "name": "Johns Hopkins Bayview Medical Center"
                }, 
                "investigator": {
                    "last_name": "Alan Schwartz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bdraper@sleepservices.net", 
                    "last_name": "Barbara Draper", 
                    "phone": "240-965-3619"
                }, 
                "contact_backup": {
                    "email": "bgrimm@dchweb.org", 
                    "last_name": "Barbara Grimm", 
                    "phone": "(240) 965-8452"
                }, 
                "facility": {
                    "address": {
                        "city": "Lanham", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20706"
                    }, 
                    "name": "Doctors Community Hospital"
                }, 
                "investigator": {
                    "last_name": "Riad Dakheel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring", 
        "overall_contact": {
            "email": "mguzman4@jhmi.edu", 
            "last_name": "Michelle Guzman", 
            "phone": "(410) 550-6336"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to demonstrate that minimally effective nasal CPAP (\u2264 6 cm H2O) delivered by the Cloud9\u2122 device reduces the number of snoring events and reduces snoring intensity in habitual, simple snorers in treatment session 3. We will test the hypothesis that the Cloud9\u2122 device will decrease the number of loud snores by 50% or decrease the overall number of snores by 50%.", 
            "measure": "Efficacy - The Cloud9\u2122 device is expected to reduce the incidence of snoring.", 
            "safety_issue": "No", 
            "time_frame": "single night of sleep"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety- Adverse events associated with the Cloud9\u2122 device (nasal or skin irritation, epistaxis and sleep disruption) will occur in fewer than 20% of the subjects in this study.", 
            "measure": "Safety - Adverse events associated with CPAP (nasal or skin irritation, epistaxis and sleep disruption) will occur in few subjects.", 
            "safety_issue": "Yes", 
            "time_frame": "two different single nights"
        }, 
        "source": "inSleep Technologies, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Doctors Community Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "NeuroTrials Research, Inc.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "inSleep Technologies, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}